Department of Chemistry and Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts.
Med Res Rev. 2014 May;34(3):596-643. doi: 10.1002/med.21299. Epub 2013 Aug 29.
In an effort to discover a noninvasive method for predicting which cancer patients will benefit from therapy targeting the EGFR and HER2 proteins, a large body of the research has been conducted toward the development of PET and SPECT imaging agents, which selectively target these receptors. We provide a general overview of the advances made toward imaging EGFR and HER2, detailing the investigation of PET and SPECT imaging agents ranging in size from small molecules to monoclonal antibodies.
为了寻找一种非侵入性的方法来预测哪些癌症患者将受益于针对 EGFR 和 HER2 蛋白的治疗，大量的研究致力于开发选择性靶向这些受体的 PET 和 SPECT 成像剂。我们提供了关于成像 EGFR 和 HER2 的进展的概述，详细介绍了从小分子到单克隆抗体等各种大小的 PET 和 SPECT 成像剂的研究。
